YIACO Stock Overview
YIACO Medical Company K.S.C.P., together with its subsidiaries, sells medicines, healthcare related products, medical equipment, and dental equipment and materials in Kuwait.
YIACO Medical Company K.S.C.P Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||د.ك0.45|
|52 Week High||د.ك0.48|
|52 Week Low||د.ك0.40|
|1 Month Change||0%|
|3 Month Change||0%|
|1 Year Change||2.27%|
|3 Year Change||-36.32%|
|5 Year Change||-75.80%|
|Change since IPO||-78.24%|
Recent News & Updates
|YIACO||KW Healthcare||KW Market|
Return vs Industry: YIACO exceeded the KW Healthcare industry which returned -24.1% over the past year.
Return vs Market: YIACO underperformed the KW Market which returned 7.2% over the past year.
|YIACO Average Weekly Movement||0%|
|Healthcare Industry Average Movement||4.8%|
|Market Average Movement||4.9%|
|10% most volatile stocks in KW Market||9.5%|
|10% least volatile stocks in KW Market||2.3%|
Stable Share Price: YIACO is less volatile than 75% of KW stocks over the past 3 months, typically moving +/- 0% a week.
Volatility Over Time: YIACO's weekly volatility (0%) has been stable over the past year.
About the Company
|1953||n/a||Sheikh Ahmad Salem Al Al Sabah||https://www.yiacokuwait.com|
YIACO Medical Company K.S.C.P., together with its subsidiaries, sells medicines, healthcare related products, medical equipment, and dental equipment and materials in Kuwait. It supplies pharmaceutical and consumer health care products; veterinary, agricultural, and public health products; skincare products; hospital, laboratory, scientific, and dental equipment and materials; hospital furniture, physiotherapy, rehabilitation, home health care, diagnostics and evaluation, respiratory, and manikins and simulator products; and sports medicine, customized prescribed wheelchairs, and adult rehabilitations. The company also owns and manages a chain of 31 retail pharmacies; operates a chain of medical diagnostic centers; and offers home care and outpatient health care services.
YIACO Medical Company K.S.C.P Fundamentals Summary
|YIACO fundamental statistics|
Is YIACO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|YIACO income statement (TTM)|
|Cost of Revenue||د.ك10.02m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.087|
|Net Profit Margin||-9.14%|
How did YIACO perform over the long term?See historical performance and comparison
Is YIACO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for YIACO?
Other financial metrics that can be useful for relative valuation.
|What is YIACO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does YIACO's PS Ratio compare to its peers?
|YIACO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ATC Advanced Technology Company K.S.C.P
TM Techno Medical
9265 Yamashita Health Care HoldingsInc
3118 Level Biotechnology
YIACO YIACO Medical Company K.S.C.P
Price-To-Sales vs Peers: YIACO is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does YIACO's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Sales vs Industry: YIACO is good value based on its Price-To-Sales Ratio (0.5x) compared to the Asian Healthcare industry average (1.7x)
Price to Sales Ratio vs Fair Ratio
What is YIACO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.5x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate YIACO's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of YIACO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: YIACO (KWD0.45) is trading below our estimate of fair value (KWD0.76)
Significantly Below Fair Value: YIACO is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is YIACO Medical Company K.S.C.P forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as YIACO Medical Company K.S.C.P has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether YIACO Medical Company K.S.C.P is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
How has YIACO Medical Company K.S.C.P performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YIACO is currently unprofitable.
Growing Profit Margin: YIACO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: YIACO is unprofitable, but has reduced losses over the past 5 years at a rate of 46.4% per year.
Accelerating Growth: Unable to compare YIACO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YIACO is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (15.5%).
Return on Equity
High ROE: YIACO has a negative Return on Equity (-845.53%), as it is currently unprofitable.
Discover strong past performing companies
How is YIACO Medical Company K.S.C.P's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: YIACO's short term assets (KWD24.0M) do not cover its short term liabilities (KWD31.3M).
Long Term Liabilities: YIACO's short term assets (KWD24.0M) exceed its long term liabilities (KWD1.4M).
Debt to Equity History and Analysis
Debt Level: YIACO has more cash than its total debt.
Reducing Debt: YIACO's debt to equity ratio has increased from 324.8% to 4235.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable YIACO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: YIACO is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 25.9% per year.
Discover healthy companies
What is YIACO Medical Company K.S.C.P current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate YIACO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate YIACO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if YIACO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if YIACO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: YIACO is not paying a notable dividend for the KW market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as YIACO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sheikh Ahmad Salem Al Al Sabah
Mr. Sheikh Ahmad Salem Al Ali Al Sabah is Vice Chairman and CEO at YIACO Medical Company K.S.C.P. since April 2018.
Experienced Management: YIACO's management team is seasoned and experienced (6.4 years average tenure).
Experienced Board: YIACO's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
YIACO Medical Company K.S.C.P's employee growth, exchange listings and data sources
- Name: YIACO Medical Company K.S.C.P
- Ticker: YIACO
- Exchange: KWSE
- Founded: 1953
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: د.ك7.704m
- Shares outstanding: 17.12m
- Website: https://www.yiacokuwait.com
- YIACO Medical Company K.S.C.P
- Sama Tower
- Salmiya, Block No. 5
- Kuwait City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|YIACO||KWSE (Kuwait Stock Exchange)||Yes||Share Capital||KW||KWD||Nov 2007|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/24 00:00|
|End of Day Share Price||2022/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.